Akeso’s Gumokimab Approved by NMPA for Plaque Psoriasis
The China National Medical Products Administration (NMPA) has approved Akeso, Inc.’s gumokimab (AK111) for the treatment of adult moderate-to-severe plaque psoriasis. According to the company, the monoclonal antibody demonstrated a 94.6% PASI 75 response rate and a 47.7% complete skin clearance rate (PASI 100) at Week 12. The drug is now poised to enter the … Read more